Literature DB >> 6594016

Short-term effects of danazol on endometrial histology.

S Jeppsson, P Mellquist, G Rannevik.   

Abstract

The synthetic steroid danazol has rapidly become the drug most commonly used in the hormonal treatment of endometriosis and its clinical and endocrine properties in women have been investigated extensively. However, little is known about the early effects of danazol on the endometrium. This study was performed in order to discover how soon after institution of danazol therapy atrophic changes can be observed in the endometrium. Ten patients with fibromyoma of the uterus and menorrhagia were treated with danazol at a dosage of 600 mg a day. During treatment, plasma estradiol values corresponded to those of the early follicular phase of a normal menstrual cycle. In 5 of the patients, endometrial biopsies were obtained after 8 weeks of therapy. Four of them had a thin endometrium of atrophic histological appearance. In view of these findings, biopsies were taken from a further 5 patients after only 4 weeks' treatment. All of these biopsies revealed a reduced endometrium and 3 of the 5 endometria were histologically clearly atrophic. Even if total resorption of endometriotic tissue usually takes a considerable time, the finding of atrophy of the uterine endometrium induced by danazol after only 4 weeks of treatment is consistent with the rapid improvement in clinical symptoms in patients with endometriosis.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6594016     DOI: 10.3109/00016348409156980

Source DB:  PubMed          Journal:  Acta Obstet Gynecol Scand Suppl        ISSN: 0300-8835


  3 in total

1.  A comparative study of danazol and norethisterone in dysfunctional uterine bleeding presenting as menorrhagia.

Authors:  M Bonduelle; J J Walker; A A Calder
Journal:  Postgrad Med J       Date:  1991-09       Impact factor: 2.401

2.  Management of dysfunctional uterine bleeding.

Authors:  C M Farquhar
Journal:  Drugs       Date:  1992-10       Impact factor: 9.546

Review 3.  Risk-benefit assessment of drugs used for the treatment of menstrual disorders.

Authors:  J M Higham; R W Shaw
Journal:  Drug Saf       Date:  1991 May-Jun       Impact factor: 5.606

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.